Consumption of Dairy Yogurt Enhanced Immune Function

Consumption of Dairy Yogurt With Rhamnogalacturonan in Korean Citrus Hallabong Peel Polysaccharide Enhanced Immune Function and Attenuated Inflammatory Response

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02535663

Enrollment

120

Registered

2015-08-28

Start date

2014-06-30

Completion date

2015-03-31

Last updated

2016-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

rhamnogalacturonan, Natural killer cell activity, interleukin-12, interferon-gamma, immune function, inflammatory

Brief summary

To investigate the impact of consumption of dairy yogurt with rhamnogalacturonan (RG) in Korean citrus Hallabong peel polysaccharide on Natural Killer (NK) cell activity and circulating cytokine levels.

Detailed description

A randomized, double-blind, placebo-controlled study was conducted on 120 nondiabetic and nonobese subjects. Over an 8 week period, the test group consumed one pack (150ml) of dairy yogurt with 50mg probiotics and 100mg Korean citrus Hallabong peel polysaccharide (60% RG, 20% mono- and di-saccharide, 5% polyphenol) each day, whereas the placebo group consumed the same product without Korean citrus Hallabong peel polysaccharide. NK cell activities (%) were measured based on the ratios of effector cells (E) (peripheral blood mononuclear cell, PBMC) from each participant to Target cell (T) (K562 cells) as 10:1, 5:1, 2.5:1 or 1.25:1.

Interventions

DIETARY_SUPPLEMENTRG

The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture

DIETARY_SUPPLEMENTPlacebo

Same product without RG

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 69 Years

Healthy volunteers

Yes

Inclusion criteria

* The levels of white blood cells under 8x10\^3/μL * males and females * 30-69 years old * nondiabetic and nonobese subjects * able to give informed consent

Exclusion criteria

* consumption of any probiotic products within 1 month before screening * unstable body weight (body-weight change \> 2 kg within 3 months before screening) * diabetes * history/presence of significant metabolic disease * pregnancy or breast-feeding * acute or chronic infection * liver disease, kidney disease, gastrointestinal disease, or any other acute or chronic disease requiring treatment * subjects taking any drugs or supplements

Design outcomes

Primary

Measure	Time frame	Description
serum cytokine concentrations	change from baseline in RG at 8 weeks	Primary outcome will be tested before and after intervention

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026